The efficacy and mechanism of surfactant therapy for critically ill infants with bronchiolitis: The Bronchiolitis Endotracheal Surfactant Study. - The Bronchiolitis Endotracheal Surfactant Study (BESS)

niversity Of Liverpool0 个研究点目标入组 284 人开始时间: 2018年8月21日最近更新: 2019年6月30日

适应症

试验速览

暂无简介。

•1.Term-born infants < 26 weeks old and preterm-born infants < 26 weeks corrected age†
•2.Diagnosis of bronchiolitis (see below)
•3.Requires conventional invasive MV via tracheal intubation
•4. Parent or person with parental responsibility has given written informed consent for trial participation
•†Premature born infants have their age corrected to account for weeks of lost gestation
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range 0
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range 0

•1.Major congenital anomalies, including complex or haemodynamically compromising cardiac anomalies.
•2.Congenital neuromuscular disease
•3.Already intubated for MV for >48 hours or likely to have been intubated for MV for >48 hours by randomisation
•4.Have received or are receiving extracorporeal membrane oxygenation (ECMO) or oscillation during this episode of bronchiolitis
•5.Have received or are receiving intratracheal administration of any surfactant during this episode of bronchiolitis
•6.Receiving MV for primary apnoea rather than respiratory failure
•7.A decision to wean to extubation has already been made
•8.Clinical judgement of futility

发起方

niversity Of Liverpool